BioWorld: The Daily Biopharmaceutical and Medical Technology …
WEBDetailed data affirm ivonescimab tops Keytruda in NSCLC trial. More than three months ago, investors first learned that ivonescimab, a PD-1/VEGF-targeting bispecific antibody from Summit Therapeutics and Akeso Pharmaceuticals Inc.,... Daily news and analysis of the global biotechnology, pharmaceutical and medical technology industries.
BioWorld MedTech: The Daily Medical Technology News Source
WEBBioWorld Premium. Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription. Daily news and analysis of the medical technology industry. In-depth coverage of business, financing, regulation, science, innovation, device approvals, clinical trials and more.
New peptide antibiotics from the human microbiome | BioWorld
WEBAug 22, 2024 · The gastrointestinal tract could be key to developing new drugs to combat resistant bacteria. Computational analysis of the human microbiome has revealed a new class of peptides with antimicrobial potential that, once synthesized, inhibited the growth of several microorganisms in vitro and in vivo. “Antimicrobial resistance is one of the greatest threats to humanity, with more and more ...
Buntanetap data gap uncapped in Parkinson’s; Annovis to
WEBJan 24, 2024 · About two months after reporting that enrollment of its phase II/III study with buntanetap in Alzheimer’s disease had completed enrollment, Annovis Bio Inc. disappointed Wall Street by saying that findings from the phase III in Parkinson’s disease – hoped for by the end of this month – would be delayed for data-cleaning reasons.
Australia - BioWorld
WEB4 days ago · Monopar Therapeutics Inc. has received Human Research Ethics Committee (HREC) clearance in Australia to initiate a phase I therapeutic trial of its novel radiopharmaceutical MNPR-101-Lu. MNPR-101-Lu combines the therapeutic radioisotope lutetium-177 (Lu-177) with Monopar’s proprietary first-in-class humanized monoclonal antibody MNPR-101 ...
China - BioWorld
WEB4 days ago · Sep. 17, 2024. By Marian (YoonJee) Chu. No Comments. Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster therapies in China. At the heart of the GLP-1 boom is a nationwide obesity problem driven by a ...
Asia biotech ecosystems roaring back in 2023 - BioWorld
WEBDec 19, 2023 · If the COVID-19 pandemic shocked countries to build self-reliance in biomedical ecosystems, the re-opening of borders in 2023 kickstarted international collaborations to grow major biohubs in Asia. Countries in the Asia Pacific region – including Singapore, China, Japan, Korea and Australia – increasingly drew overseas investors and collaborators, helping each country grow national biotech ...
The human brain remodels gray and white matter during pregnancy
WEB4 days ago · The map of the human brain is not a static image of the cellular architecture of the central nervous system (CNS). Throughout life, all living beings are born, develop and age. The brain of pregnant mothers reflects a dynamic that modifies this general picture. A collaboration of scientists from the University of California has studied the changes in the adult brain during pregnancy and ...
Methodology of BioWorld charts
WEBBioWorld data methodology. Clinical. BioWorld biopharma clinical, regulatory and conference charts include worldwide news of phase I, phase II and phase III clinical development by biopharmaceutical companies developing therapeutics, as well as all actions by global regulatory authorities and clinical data reported at industry conferences.
Cumulus Oncology licenses small molecules from GPR68 drug
WEBAug 20, 2024 · Cumulus Oncology Ltd. has announced key milestones, in partnership with collaborator Leadxpro AG, in the companies’ protein structure-driven GPR68 drug discovery project. The partners announced their collaboration in July last year to develop small molecules against GPR68.